SpringWorks Therapeutics (NASDAQ:SWTX) doses
first patient in a Phase 1b clinical trial evaluating its
investigational gamma secretase inhibitor, nirogacestat, in combination
with GlaxoSmithKline’s (NYSE:GSK)
investigational anti-B-cell maturation antigen (BCMA) antibody-drug
conjugate, belantamab mafodotin, in patients with relapsed or refractory
multiple myeloma.
The nirogacestat and belantamab mafodotin combination is being evaluated as a sub-study in GSK’s ongoing DREAMM-5 platform trial.
The Phase 1b combination trial is being advanced
subject to a global clinical trial collaboration agreement that both the
companies signed in June 2019.
The study will include two parts, a dose exploration phase and a cohort expansion phase.
https://seekingalpha.com/news/3584844-dosing-underway-in-springworks-early-stage-combination-study-in-multiple-myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.